HealthEquity Terminates CTO Eli Rosner's Employment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy HQY?
On April 6, HealthEquity announced that the employment of Eli Rosner, the Company's Chief Technology Officer, will be terminated by the Company without cause, effective April 17, 2026. Sunil Rajasekar, the Company's Executive Vice President, Chief Product and Strategy Officer, will be responsible for overseeing the Company's technology organization as of that date.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HQY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HQY
Wall Street analysts forecast HQY stock price to rise
11 Analyst Rating
9 Buy
1 Hold
1 Sell
Moderate Buy
Current: 86.330
Low
89.00
Averages
117.09
High
129.00
Current: 86.330
Low
89.00
Averages
117.09
High
129.00
About HQY
HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BMO Upgrades HealthEquity to Outperform Amid Growth Optimism
- Rating Upgrade: BMO Capital Markets upgraded HealthEquity's rating from Market Perform to Outperform, with analyst Sean Dodge highlighting that fears related to AI are overblown, suggesting the current stock price offers a compelling entry point for investors.
- Increased Growth Expectations: Dodge raised HealthEquity's long-term growth estimates from mid-single digits/high single digits to high single digits/low double digits, indicating that the recent launch of the Marketplace business will create additional monetization opportunities for its member base, further driving revenue growth.
- Price Target Increase: BMO raised HealthEquity's price target from $85 to $105 per share, reflecting confidence in the company's future performance and anticipating benefits from the successful implementation of its Marketplace business.
- Strong Financial Performance: HealthEquity's recent non-GAAP EPS of $0.95 exceeded expectations by $0.05, while revenue of $334.6 million surpassed estimates by $1.78 million, indicating ongoing improvements in the company's financial health.
See More
Medicare Advantage Payments Increase by 2.48%, Boosting Insurer Stocks
- Payment Increase Impact: The Centers for Medicare & Medicaid Services announced a 2.48% increase in Medicare Advantage payments for 2027, leading to significant stock price surges among major healthcare insurers in after-hours trading on Monday, reflecting market optimism regarding insurers' profitability.
- Significant Market Reaction: Following this announcement, Centene Corporation (CNC) saw a 4.3% increase, UnitedHealth Group (UNH) rose by 7.8%, and Humana (HUM) surged by 11%, indicating heightened investor confidence in the healthcare insurance sector's outlook.
- Quantitative Rating Insights: According to Quant ratings, HealthEquity (HQY) leads with a score of 3.57, followed by Centene (3.38) and Alignment Healthcare (3.30), providing investors with valuable insights for selecting insurance providers based on performance metrics.
- Future Outlook: This payment increase is expected to generate an additional $18 billion in revenue for insurers, further driving industry growth while potentially influencing future premium rates and benefit structures, thereby enhancing the competitive positioning of insurance companies.
See More
HealthEquity Appoints New Board Member to Enhance Governance
- Board Expansion: HealthEquity announced the election of William Gassen, CEO of Sanford Health, to its board effective March 26, 2026, increasing the board to 10 members, 8 of whom are independent, thereby enhancing corporate governance.
- Rich Industry Experience: Gassen's leadership experience at Sanford Health will provide HealthEquity with deep insights into healthcare delivery and financing, helping the company better address the challenges faced by consumers, providers, and employers in the healthcare system.
- Focus on Affordability: Gassen emphasized that affordability in healthcare remains a significant challenge for many families and employers, and HealthEquity plays a crucial role in helping people prepare for healthcare expenses, further solidifying the company's market position.
- Educational Background and Professional Experience: Gassen holds a bachelor's degree in criminal justice and a J.D. from the University of South Dakota, and has held several senior leadership roles at Sanford Health, bringing a diverse perspective to the board.
See More
HEALTHEQUITY NAMES BILL GASSEN, CEO OF SANFORD HEALTH, TO ITS BOARD OF DIRECTORS
Health Equity Appointment: Bill Gassen has been appointed as the CEO of Sanford Health, focusing on health equity initiatives.
Board of Directors: Gassen will also serve on the Board of Directors, contributing to strategic decisions and governance.
See More
HealthEquity Reports Significant Q4 Growth
- Revenue and Net Income Growth: HealthEquity reported a 7% year-over-year revenue increase to $334.6 million in Q4, with net income soaring 89% to $49.7 million, indicating strong market performance and enhanced profitability.
- HSA Account Expansion: The company added a record 550,000 Health Savings Accounts (HSAs) in Q4, bringing the total to 17.8 million accounts, reflecting robust growth potential and an expanding customer base in the health savings market.
- Shareholder Returns and Cash Flow: HealthEquity returned over $300 million to shareholders through its share repurchase program, reducing diluted shares by approximately 3%, while generating $457 million in cash flow from operations, enhancing financial flexibility.
- Future Outlook and Guidance: The company expects fiscal 2027 revenue to be between $1.405 billion and $1.415 billion, with GAAP net income projected between $239 million and $246 million, demonstrating confidence in future growth and market opportunities.
See More
HealthEquity (HQY) Q4 2026 Earnings Transcript
See More
BMO Upgrades HealthEquity to Outperform Amid Growth Optimism
- Rating Upgrade: BMO Capital Markets upgraded HealthEquity's rating from Market Perform to Outperform, with analyst Sean Dodge highlighting that fears related to AI are overblown, suggesting the current stock price offers a compelling entry point for investors.
- Increased Growth Expectations: Dodge raised HealthEquity's long-term growth estimates from mid-single digits/high single digits to high single digits/low double digits, indicating that the recent launch of the Marketplace business will create additional monetization opportunities for its member base, further driving revenue growth.
- Price Target Increase: BMO raised HealthEquity's price target from $85 to $105 per share, reflecting confidence in the company's future performance and anticipating benefits from the successful implementation of its Marketplace business.
- Strong Financial Performance: HealthEquity's recent non-GAAP EPS of $0.95 exceeded expectations by $0.05, while revenue of $334.6 million surpassed estimates by $1.78 million, indicating ongoing improvements in the company's financial health.
See More
Medicare Advantage Payments Increase by 2.48%, Boosting Insurer Stocks
- Payment Increase Impact: The Centers for Medicare & Medicaid Services announced a 2.48% increase in Medicare Advantage payments for 2027, leading to significant stock price surges among major healthcare insurers in after-hours trading on Monday, reflecting market optimism regarding insurers' profitability.
- Significant Market Reaction: Following this announcement, Centene Corporation (CNC) saw a 4.3% increase, UnitedHealth Group (UNH) rose by 7.8%, and Humana (HUM) surged by 11%, indicating heightened investor confidence in the healthcare insurance sector's outlook.
- Quantitative Rating Insights: According to Quant ratings, HealthEquity (HQY) leads with a score of 3.57, followed by Centene (3.38) and Alignment Healthcare (3.30), providing investors with valuable insights for selecting insurance providers based on performance metrics.
- Future Outlook: This payment increase is expected to generate an additional $18 billion in revenue for insurers, further driving industry growth while potentially influencing future premium rates and benefit structures, thereby enhancing the competitive positioning of insurance companies.
See More
HealthEquity Appoints New Board Member to Enhance Governance
- Board Expansion: HealthEquity announced the election of William Gassen, CEO of Sanford Health, to its board effective March 26, 2026, increasing the board to 10 members, 8 of whom are independent, thereby enhancing corporate governance.
- Rich Industry Experience: Gassen's leadership experience at Sanford Health will provide HealthEquity with deep insights into healthcare delivery and financing, helping the company better address the challenges faced by consumers, providers, and employers in the healthcare system.
- Focus on Affordability: Gassen emphasized that affordability in healthcare remains a significant challenge for many families and employers, and HealthEquity plays a crucial role in helping people prepare for healthcare expenses, further solidifying the company's market position.
- Educational Background and Professional Experience: Gassen holds a bachelor's degree in criminal justice and a J.D. from the University of South Dakota, and has held several senior leadership roles at Sanford Health, bringing a diverse perspective to the board.
See More
HEALTHEQUITY NAMES BILL GASSEN, CEO OF SANFORD HEALTH, TO ITS BOARD OF DIRECTORS
Health Equity Appointment: Bill Gassen has been appointed as the CEO of Sanford Health, focusing on health equity initiatives.
Board of Directors: Gassen will also serve on the Board of Directors, contributing to strategic decisions and governance.
See More
HealthEquity Reports Significant Q4 Growth
- Revenue and Net Income Growth: HealthEquity reported a 7% year-over-year revenue increase to $334.6 million in Q4, with net income soaring 89% to $49.7 million, indicating strong market performance and enhanced profitability.
- HSA Account Expansion: The company added a record 550,000 Health Savings Accounts (HSAs) in Q4, bringing the total to 17.8 million accounts, reflecting robust growth potential and an expanding customer base in the health savings market.
- Shareholder Returns and Cash Flow: HealthEquity returned over $300 million to shareholders through its share repurchase program, reducing diluted shares by approximately 3%, while generating $457 million in cash flow from operations, enhancing financial flexibility.
- Future Outlook and Guidance: The company expects fiscal 2027 revenue to be between $1.405 billion and $1.415 billion, with GAAP net income projected between $239 million and $246 million, demonstrating confidence in future growth and market opportunities.
See More
HealthEquity (HQY) Q4 2026 Earnings Transcript
See More
